Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis

• Published in: Journal of affective disorders Vol. 282; pp. 1153 - 1160
• Main Authors: Suchting, Robert, Tirumalaraju, Vaishali, Gareeb, Rida, Bockmann, Taya, de Dios, Constanza, Aickareth, Jacob, Pinjari, Omar, Soares, Jair C., Cowen, Phil J., Selvaraj, Sudhakar
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2021
• Subjects: Anti-depressants; Antidepressive Agents - therapeutic use; Depressive Disorder - drug therapy; Humans; MAOI; Monoamine oxidase inhibitors; Monoamine Oxidase Inhibitors - therapeutic use; Network Meta-Analysis; Randomized Controlled Trials as Topic; Anti-depressants; Monoamine oxidase inhibitors; Network meta-analysis; MAOI
• ISSN: 0165-0327; 1573-2517
• DOI: 10.1016/j.jad.2021.01.021

•Network meta-analysis evaluate a set of MAOIs and other antidepressants.•All antidepressants demonstrated superiority to placebo.•Phenelzine demonstrated the strongest evidence for efficacy.•Clomipramine demonstrate the strongest evidence for acceptability.•Results support reconsidering the use of MAOIs in treating depression. Monoamine oxidase inhibitors (MAOIs) were the first class of modern antidepressants; however, they are under-utilized as compared to the newer antidepressants. In this systematic review, network meta-analysis was used to investigate the comparative efficacy and acceptability of MAOIs for depressive disorders. Overall, the network meta-analysis included 52 double-blind, randomized controlled trials (RCTs) that compared 14 antidepressants or placebo. Across studies, the mean arm size was n = 58 participants from a total N = 6462 (5309 active drug; 1153 placebo). Except fluvoxamine, all antidepressants demonstrated superior efficacy to placebo, and none demonstrated substantially better or worse all-cause dropout rates. Phenelzine demonstrated superior evidence for efficacy compared to all other treatments, and clomipramine demonstrated superior evidence for acceptability compared to all other treatments. The study is primarily limited by low estimate precision due to a relative paucity of studies for some of the included treatment conditions. Further evidence is required to study the relative efficacy of MAOIs against newer antidepressants. The results of this analysis largely support the re-evaluation of the use of MAOIs as antidepressant agents in the treatment algorithm of depression.